1-4 of 4
Zhimei Wang
Close
Sort by
Journal Articles

Zanubrutinib, Polatuzumab Vedotin and Rituximab (ZPR) Combination Regimen for Relapsed/Refractory Patients with Diffuse Large B-Cell Lymphoma

Yian Zhang, Ling Yuan, Jingli Zhuang, Zhimei Wang, Xuejiao Zhang, Weiguang Wang, Peng Liu
Journal: Blood
Blood (2023) 142 (Supplement 1): 6304.
https://doi.org/10.1182/blood-2023-185411
Published: 2023
Journal Articles

Clinical Characterization of Hepatic Light Chain Amyloidosis in the Chinese Population: A Single-Center Retrospective Analysis

Chen Chen, Chenqi Yu, Jing Li, Weiguang Wang, Zhimei Wang, Lu-Ya Cheng, Fei-fei Chen, Jiadai Xu, Tianhong Xu, Yang Yang, Wenjing Wang, Pu Wang, Peng Liu
Journal: Blood
Blood (2023) 142 (Supplement 1): 6745.
https://doi.org/10.1182/blood-2023-186600
Published: 2023
Journal Articles

Toll-Like Receptor-7 Agonist Directly Inhibits the Growth and Induces Apoptosis of MLL-AF9 Leukemia Cells in Vitro and in Vivo

Xueqing Liang, MD, PhD, Ashish Kumar, MBBS, PhD, Zhimei Wang, MD, Brenda Weigel, MSc, MD, Bruce R Blazar, M.D., Wei Chen, MD, PhD
Journal: Blood
Blood (2008) 112 (11): 2989.
https://doi.org/10.1182/blood.V112.11.2989.2989
Published: 2008
Journal Articles

Toll-Like Receptor Agonists Induce Immunogeneicity and Apoptosis of Acute Myeloid Leukemia Cells.

Maki Shindo, MD, PhD, Xueqing Liang, MD PhD, Zhimei Wang, MD, Jeffery S. Miller, MD, Martin Carroll, MD, Wei Chen, MD PhD
Journal: Blood
Blood (2007) 110 (11): 160.
https://doi.org/10.1182/blood.V110.11.160.160
Published: 2007